Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Oct 26;10(10):CD000545.
doi: 10.1002/14651858.CD000545.pub5.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

Nilesh Chande  1 , Cassandra M Townsend, Claire E Parker, John K MacDonald
Affiliations
Meta-Analysis

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

Nilesh Chande et al. Cochrane Database Syst Rev. .

Abstract

Background: The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease.

Objectives: The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease.

Search methods: We searched MEDLINE, EMBASE and the Cochrane Library from inception to 30 October 2015. Review articles and conference proceedings were also searched to identify additional studies.

Selection criteria: Randomized controlled trials (RCTs) of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion.

Data collection and analysis: Data were extracted by two independent observers based on the intention-to-treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria.

Main results: Thirteen RCTs (n = 1211 patients) of azathioprine and 6-mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was no statistically significant difference in clinical remission rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55). There was no statistically significant difference in clinical improvement rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62). There was a statistically significant difference in steroid sparing (defined as prednisone dose < 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty-four per cent (47/163) of azathioprine patients were able to reduce their prednisone dose to < 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. There was no statistically significant difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid-free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90). The combination of azathioprine and infliximab was significantly superior to infliximab alone for induction of steroid-free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid-free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47). Azathioprine or 6-mercaptopurine therapy was found to be no better at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49) and 5-aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91). There were no statistically significant differences in withdrawals due to adverse events between azathioprine or 6-mercaptopurine and methotrexate (RR 0.78, 95% CI 0.23 to 2.71); between azathioprine or 6-mercaptopurine and 5-aminosalicylate or sulfasalazine (RR 0.98, 95% CI 0.38 to 2.54); between azathioprine and infliximab (RR 1.47, 95% CI 0.96 to 2.23); or between the combination of azathioprine and infliximab and infliximab (RR 1.16, 95% CI 0.75 to 1.80). Common adverse events in the active comparator trials included nausea, abdominal pain, pyrexia and headache.

Authors' conclusions: Azathioprine and 6-mercaptopurine offer no advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. Antimetaboilte therapy may allow patients to reduce steroid consumption. Adverse events were more common in patients receiving antimetabolites although differences with placebo were not statistically significant. Azathioprine therapy is inferior to infliximab for induction of steroid-free remission. However, the combination of azathioprine and infliximab was superior to infliximab alone for induction of steroid-free remission.

PubMed Disclaimer

Conflict of interest statement

Nilesh Chande has received fees for consultancy from Abbott/AbbVie and Ferring, fees for lectures from Abbott and Janssen, travel expenses from Merck and has stock/stock options in Pfizer, Glaxo Smith Kline, Proctor and Gamble and Johnson and Johnson. All of these financial activities are outside the submitted work.

Cassandra M Townsend: None known

Claire E Parker: None known

John K MacDonald: None known

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Ardizzone 2003 {published data only}
    1. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator‐blind study. Digestive and Liver Disease 2003;35(9):619‐27. - PubMed
    1. Ardizzone S, Bollani S, Manzionna G, Molteni P, Bianchi Porro G. Controlled Trial Comparing Intravenous Methotrexate and Oral Azathioprine for Chronic Active Crohn's Disease: Preliminary Report. Gastroenterology 1999;116(4):A662‐3.
Candy 1995 {published data only}
    1. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674‐8. - PMC - PubMed
Colombel 2010 {published data only}
    1. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383‐95. - PubMed
    1. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. Supplementary Appendix. New England Journal of Medicine 2010;362.
    1. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with Crohn's disease ‐ A SONIC post hoc analysis. Alimentary Pharmacology and Therapeutics 2015;41(8):734‐46. - PubMed
    1. Colombel JF, Rutgeerts P, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitzg D, et al. SONIC: a randomized, double‐blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. United European Gastroenterology Week 2008.
    1. Sandborn W, Rutgeerts P, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. SONIC Study: A Randomized, double‐blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Inflammatory Bowel Diseases 2009;15:S13.
Ewe 1993 {published data only}
    1. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105(2):367‐72. - PubMed
    1. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Meyer zum Buschenfelde KH, et al. Azathioprine in combination with prednisolone in active Crohn's disease. Gastroenterology 1992;102(4 Part 2):A 621. - PubMed
Klein 1974 {published data only}
    1. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66(5):916‐22. - PubMed
Mantzaris 2004 {published data only}
    1. Mantzaris GJ, Ployzou P, Karagiannidis A, Christidou A, Koilakou S, Tsounis D, et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology 2004;126(4 Suppl 2):A54.
Maté‐Jiménez 2000 {published data only}
    1. Hermida C, Cantero J, Moreno‐Otero R, Mate‐Jimenez J. Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut 1999;45(Suppl V):A132.
    1. Maté‐Jiménez J, Hermida C, Cantero‐Perona J, Moreno‐Otero R. 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2000;12(11):1227‐33. - PubMed
Oren 1997 {published data only}
    1. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology 1997;92(12):2203‐9. - PubMed
Present 1980 {published data only}
    1. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine 1980;302(18):981‐7. - PubMed
    1. Present DH, Wisch N, Glass JL, Korelitz BI. The efficacy of immunosuppressive therapy in Crohn's disease. A randomized long term double blind study. Gastroenterology 1977;72(5ii):A‐91.
Reinisch 2008 {published data only}
    1. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology 2008;103(9):2284‐92. - PubMed
Rhodes 1971 {published data only}
    1. Rhodes J, Bainton D, Beck P. Azathioprine in Crohn's disease. Lancet 1970;2(7683):1142. - PubMed
    1. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7737):1273‐6. - PubMed
Summers 1979 {published data only}
    1. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77(4 Pt 2):898‐906. - PubMed
    1. Singleton J, Law D, Kelley M, Mekhjian H, Sturdevant R. National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology 1979;77(4 Pt 2):870‐82. - PubMed
    1. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847‐69. - PubMed
    1. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2):829‐42. - PubMed
Willoughby 1971 {published data only}
    1. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7731):944‐7. - PubMed
    1. Willoughby JM, Kumar P, Beckett J, Dawson AM. A double‐blind trial of azathioprine in Crohn's disease. Gut 1971;12(10):864. - PubMed

References to studies excluded from this review

Bianchi Porro 1982 {published data only}
    1. Bianchi Porro G, Ardizzone S, Bollani S, Duca A, Manzionna G, Molteni P. Controlled trial comparing intravenous methotrexate and oral azathioprine for chronic active Crohn's disease: preliminary report. Gut 1982;23(10):285.
Broekman 2015 {published data only}
    1. Broekman MM, Coenen MJ, Franke B, Derijks LJ, Vermeulen SH, Wong DR, et al. Azathioprine and 6‐mercaptopurine are equally effective in thiopurine naive IBD patients. Gastroenterology 2015;148(4 Suppl 1):S269.
Chebli 2007 {published data only}
    1. Chebli JM, Gaburri PD, Souza AF, Pinto AL, Chebli LA, Felga GE, et al. Long‐term results with azathioprine therapy in patients with corticosteroid‐dependent Crohn’s disease: Open‐label prospective study. Gastroenterology 2007;22:268‐74. - PubMed
Colombel 2003 {published data only}
    1. Colombel JF, Lemann M, Bouhnik Y, Duclos B, Soule JC, Lerebours E, et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology 2003;124(4 Suppl 1):A196‐7.
Cosnes 2012 {published data only}
    1. Balzola F, Cullen G, Ho GT, Russell RK. Early administration of azathioprine versus conventional management of Crohn's disease: A randomized controlled trial. Inflammatory Bowel Disease Monitor 2013;14(1):23‐4.
    1. Cosnes J, Bourrier A, Bouhnik Y, Laharie D, Nahon S, Bonnet J, et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease. A randomized study. Gastroenterology 2012;142(5 Suppl 1):S161.
D'Haens 2008 {published data only}
    1. Costes L, Colombel JF, Mary JY, Duclos B, Veyrac M, Dupas JL, et al. Long term follow‐up of a cohort of steroid‐dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008;134(4 Suppl 1):A134.
    1. D'Haens G, Baert F, Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step‐up therapy in newly diagnosed Crohn’s disease. Gastroenterology 2006;130(4 Suppl 2):A110.
    1. D'Haens G, Baert F, Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660‐7. - PubMed
Dassopoulos 2014 {published data only}
    1. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, et al. Randomised clinical trial: Individualised vs. weight‐based dosing of azathioprine in Crohn's disease. Alimentary Pharmacology and Therapeutics 2014;39(2):163‐75. - PMC - PubMed
    1. Dassopoulos T, Martin CF, Galanko J, Wolf DC, Dubinsky M, Sandler RS, et al. A randomized trial of metabolite‐adjusted versus weight‐based dosing of azathioprine (AZA) in Crohn's disease (CD). Gastroenterology 2009;136(5 Suppl 1):T1192.
Dejaco 2003 {published data only}
    1. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Alimentary Pharmacology and Therapeutics 2003;18:1113–20. - PubMed
Eigner 2015 {published data only}
    1. Eigner W, Vafai‐Tabrizi F, Bashir K, Primas C, Vogelsang H. Azathioprine versus mycophenolate mofetil in combination with anti‐TNF alpha agents in the management of Crohn's disease. Journal of Crohn's and Colitis 2015;9:S326.
Israeli 2015 {published data only}
    1. Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y, et al. Oral administration of non‐absorbable delayed release 6‐mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. Clinical and Experimental Immunology 2015;181(2):362‐72. - PMC - PubMed
    1. Israeli E, Goldin E, Fishman S, Konikoff FM, Lavy A, Chowers Y, et al. Oral administration of non‐absorbable delayed release 6‐mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates crohn's disease with low rate of side effects: Results of double blind phase II clinical trial. Gastroenterology 2014;1):S‐587. - PMC - PubMed
    1. Israeli E, Lalazar G, Hemed N, Caraco Y, Goldin E, Ilan Y. Promotion of CD4+CD25+FOXP3+ regulatory cells by oral administration of locally acting delayed release low‐dose 6MP formulation alleviated Crohn's disease: Results of phase I/II clinical trial. Gastroenterology 2010;1):S519.
Khanna 2014 {published data only}
    1. Khanna R, Levesque BG, Bressler B, Zou G, Stitt L, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease: A community‐based cluster randomized trial. Journal of Crohn's and Colitis 2014;8:S2‐S3.
Lémann 2006 {published data only}
    1. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al. Infliximab plus azathioprine for steroid‐dependent Crohn’s disease patients: A randomized placebo‐controlled trial. Gastroenterology 2006;130:1054–61. - PubMed
Lloyd‐Still 1990 {published data only}
    1. Lloyd‐Still JD. Azathioprine and the treatment of chronic inflammatory bowel disease. Journal of Pediatrics 1990;117(5):732‐5. - PubMed
Ludwig 1999 {published data only}
    1. Ludwig D, Strange EF. Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one‐year follow‐up study. German Imurek Study Group. Zeitschrift für Gastroenterologie 1999;37(11):1085‐91. - PubMed
Mantzaris 2009 {published data only}
    1. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn’s disease. Inflammatory Bowel Diseases 2009;15:375–82. - PubMed
Markowitz 2000 {published data only}
    1. Markowitz J, Grancher K, Kohn N, Daum F. Relationship of leukopenia to 6MP induced remission of Crohn's Disease (CD). Journal of Pediatric Gastroenterology and Nutrition 1998;27(4):465.
    1. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6‐mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119(4):895‐902. - PubMed
Miehsler 2001 {published data only}
    1. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine‐intolerant patients with chronic active Crohn's disease?. American Journal of Gastroenterology 2001;96(3):782‐7. - PubMed
Neurath 1999 {published data only}
    1. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer Zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gastroenterology 1998;114(4 Pt 2):A487. - PMC - PubMed
    1. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44(5):625‐8. - PMC - PubMed
Panés 2013 {published data only}
    1. Balzola F, Cullen G, Ho GT, Russell RK. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Inflammatory Bowel Disease Monitor 2013;14(1):23.
    1. Panés J, López‐Sanromán A, Bermejo F, García‐Sánchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145(4):766‐74. - PubMed
Reinshagen 2007 {published data only}
    1. Reinshagen M, Schütz E, Armstrong VW, Behrens C, Tirpitz C, Stallmach A, et al. 6‐Thioguanine nucleotide–adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clinical Chemistry 2007;53(7):1306–14. - PubMed
Rosenberg 1975 {published data only}
    1. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases 1975;20(8):721‐6. - PubMed
Sans 2011 {published data only}
    1. Sans M, Roman ALS, Esteve M, Bermejo F, Garcia‐Sanchez V, Torres Y, et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011;140(5 Suppl 1):S109.
Watson 1974 {published data only}
    1. Watson WC, Bukosdky M. Azathioprine in management of Crohn's disease: A randomized cross‐over study. Gastroenterology 1974;66:796 (Abstract).

Additional references

Alstead 1990
    1. Alstead EM, Ritchie JK, Lennard‐Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99(2):443‐6. - PubMed
Avery‐Jones 1966
    1. Avery‐Jones F, Lennard‐Jones JE, Hinton JM, Reeves WG. Dangers of immuno‐suppressive drugs in ulcerative colitis (letter). British Medical Journal 1966;1:1418. - PMC - PubMed
Bouhnik 1996
    1. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long‐term follow‐up of patients with Crohn's disease treated with azathioprine or 6‐mercaptopurine. Lancet 1996;347(8996):215‐9. - PubMed
Brooke 1969
    1. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969;2(7621):612‐4. - PubMed
Brooke 1970
    1. Brooke BN, Javett SL, Davison OW. Further experience with azathioprine for Crohn's disease. Lancet 1970;2(7682):1050‐3. - PubMed
Brooke 1976
    1. Brooke BN, Cave DR, King DW. Place of azathioprine for Crohn's disease. Lancet 1976;1(7968):1041‐2. - PubMed
Brown 1970
    1. Brown CH, Achkar E. Azathioprine therapy for inflammatory bowel disease. A preliminary report. American Journal of Gastroenterology 1970;54(4):363‐77. - PubMed
Colonna 1994
    1. Colonna T, Korelitz BI. The role of leukopenia in the 6‐mercaptopurine‐induced remission of refractory Crohn's disease. American Journal of Gastroenterology 1994;89(3):362‐6. - PubMed
Connell 1993
    1. Connell WR, Kamm MA, Ritchie JK, Lennard‐Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34(8):1081‐5. - PMC - PubMed
Connell 1994
    1. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard‐Jones JE. Long‐term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343(8908):1249‐52. - PubMed
D'Haens 1995
    1. D'Haens G, Callens J, Hiele M, Peeters M, Rutgeerts P. Reduction of neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease. Gastroenterology 1995;108:A809.
D'Haens 1997
    1. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112(5):1475‐81. - PubMed
Drucker 1970
    1. Drucker WR, Jeejeebhoy KN. Azathioprine: an adjunct to surgical therapy of granulomatous enteritis. Annals of Surgery 1970;172(4):618‐26. - PMC - PubMed
Fausa 1971
    1. Fausa O, Gjone E. Azathioprine (Imurel) therapy in Crohn's disease. Acta Medica Scandinavica 1971;190(3):211‐2. - PubMed
Fraser 2002
    1. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Alimentary Pharmacology and Therapeutics 2002;16(7):1225‐32. - PubMed
Gisbert 2008
    1. Gisbert JP, Gomollón F. Thiopurine‐induced myelotoxicity in patients with inflammatory bowel disease: a review. American Journal of Gastroenterology 2008;103(7):1783‐800. - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. - PMC - PubMed
Haber 1986
    1. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6‐mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91(4):982‐6. - PubMed
Hanauer 2004
    1. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology 2004;2(7):542‐53. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Javett 1972
    1. Javett SL, Hoffmann VJ. Azathioprine in acute Crohn's disease. South African Medical Journal 1972;46(38):1369. - PubMed
Kessler 1995
    1. Kessler BH, Pettei MJ, Weinstein T, Gold DM, Levine JJ. 6‐Mercaptopurine (6‐MP) in pediatric Crohn's disease: high dose versus conventional dose. Gastroenterology 1995;108:A848.
Khan 2011
    1. Khan K, Dubinksky M, Ford A, Ullman T, Talley N, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel Disease: A systematic review and meta‐analysis. American Journal of Gastroenterology 2011;106:630‐42. - PubMed
Korelitz 1981
    1. Korelitz BI, Present DH. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981;80(1):193‐6. - PubMed
Korelitz 1985
    1. Korelitz BI, Present DH. Favorable effect of 6‐mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences 1985;30(1):58‐64. - PubMed
Korelitz 1993
    1. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long‐term experience with 6‐mercaptopurine in the treatment of Crohn's disease. American Journal of Gastroenterology 1993;88(8):1198‐205. - PubMed
Lemann 1990
    1. Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Traitment de la maladie de Crohn par l'azathioprine ou la 6‐mercaptopurine. Gastroentérologie Clinique et Biologique 1990;14(6‐7):548‐54. - PubMed
Lennard 1983
    1. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6‐mercaptopurine metabolites and neutropenia. British Journal of Clinical Pharmacology 1983;16(4):359‐63. - PMC - PubMed
Lennard 1989
    1. Lennard L, Loon JA, Weinshilboum RM. Pharmacogenitics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics 1989;46(2):149‐54. - PubMed
Lennard 1992
    1. Lennard L. The clinical pharmacology of 6‐mercaptopurine. European Journal of Clinical Pharmacology 1992;43(4):329‐39. - PubMed
Lennard‐Jones 1972
    1. Lennard‐Jones JE, Williams CB. Azathioprine in the treatment of Crohn's disease. Proceedings of the Royal Society of Medicine 1972;65:291‐3. - PMC - PubMed
Lennard‐Jones 1981
    1. Lennard‐Jones JE. Azathioprine and 6‐mercaptopurine have a role in the treatment of Crohn's disease. Digestive Diseases and Sciences 1981;26(4):364‐8. - PubMed
Markowitz 1990
    1. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long‐term 6‐mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99(5):1347‐51. - PubMed
Nyman 1985
    1. Nyman M, Hansson I, Eriksson S. Long‐term immunosuppressive treatment in Crohn's disease. Scandinavian Journal of Gastroenterology 1985;20(10):1197‐203. - PubMed
O'Brien 1991
    1. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6‐mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101(1):39‐46. - PubMed
Papp 1974
    1. Papp JP, Watson DW, Bull FE. Azathioprine treatment in Crohn's disease. American Journal of Gastroenterology 1974;61(2):136‐42. - PubMed
Patterson 1971
    1. Patterson JF, Norton RA, Schwartz RS. Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. American Journal of Digestive Diseases 1971;16(2):327‐32. - PubMed
Perrault 1991
    1. Perrault J, Greseth JL, Tremaine WJ. 6‐Mercaptopurine therapy in selected cases of corticosteroid‐dependent Crohn's disease. Mayo Clinic Proceedings 1991;66(5):480‐4. - PubMed
Present 1989
    1. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6‐Mercaptopurine in the management of inflammatory bowel disease: short‐ and long‐term toxicity. Annals of Internal Medicine 1989;111(8):641‐9. - PubMed
Rosman 1973
    1. Rosman M, Bertino JR. Azathioprine. Annals of Internal Medicine 1973;79(5):694‐700. - PubMed
Sahasranaman 2008
    1. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology 2008;64:753‐67. - PubMed
Sandborn 1995
    1. Sandborn WJ, Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109(6):1808‐17. - PubMed
Sandborn 1996
    1. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6‐mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology 1996;91(3):423‐33. - PubMed
Sandborn 1999
    1. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid‐treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117(3):527‐35. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Shah 1991
    1. Shah MD, Berman WF. Use of azathioprine in nine children with Crohn's disease. Virginia Medical Quarterly 1991;118(3):169‐70. - PubMed
Verhave 1990
    1. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. Journal of Pediatrics 1990;117(5):809‐14. - PubMed
Wallensten 1972
    1. Wallensten S, Persson S. Azathioprine therapy for Crohn's disease. Acta Chirurgica Scandinavica 1972;138(5):521‐6. - PubMed
Weinshilboum 1980
    1. Weinshilboum RN, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 1980;32(5):651‐62. - PMC - PubMed

References to other published versions of this review

Chande 2013
    1. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] - DOI - PubMed
Pearson 1995
    1. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6‐mercaptopurine in Crohn's disease. A meta‐analysis. Annals of Internal Medicine 1995;123(2):132‐42. - PubMed
Prefontaine 2010
    1. Prefontaine E, MacDonald JK, Sutherland LR. Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD000545.pub3] - DOI - PubMed

Publication types

MeSH terms